Editas Medicine Q1 2024 Earnings Call Transcript

Quartr
Provided by Quartr
May 8, 2024

There are 18 speakers on the call.

Operator

Good morning, and welcome to the Editas Medicine First Quarter 2024 Conference Call. All participants are now in a listen only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Christy Barnett, Corporate Communications and Investor Relations at Editas Medicine.

Speaker 1

Thank you. Good morning, everyone, and welcome to our Q1 2024 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available in the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q and A.

Speaker 1

As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10 ks, which is on file with the SEC as updated by our subsequent filings. In addition, any forward looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward looking statements even if our views change. Now I will turn the call over to our CEO, Gilmore O'Neill.

Speaker 2

Thanks, Christy, and good morning, everyone. Thank you for joining us today on Editas' Q1 2024 earnings call. With me today are 4 members of the Editas executive team: our Chief Medical Officer, Baisong Mai our Chief Scientific Officer, Linda Berkley our Chief Financial Officer, Eric Lucira and our Chief Commercial and Strategy Officer, Karen Dierdorf. We are pleased with Editas' Editas' momentum and progress in the Q1 of 2024. Editas' goal is to deliver life changing medicines patients with previously untreatable or undertreated genetically determined diseases.

Speaker 2

And our vision and focus strategy is to position Editas as a leader in in vivo programmable gene editing. 3 pillars underpin our strategy. The first of those pillars is to drive ReniCell, an edited cell therapy for hemoglobinopathies and formerly known as EDIT-three zero one toward BLA and commercialization. The second is to build an in vivo editing pipeline. And the third is to increase business development activities with a particular focus on monetizing our very strong intellectual property.

Speaker 2

At the start of 2024, we announced the following 2024 objectives. For ReniCell, we will provide a clinical update from the RUBY trial for severe sickle cell disease and the Edithal trial for transfusion dependent beta thalassemia in mid-twenty 24 and by year end 2024. We will complete adult cohort enrollment and initiate the adolescent cohort in Rubi and continue enrollment in Edithal. For our in vivo pipeline, we will establish in vivo preclinical proof of concept for an undisclosed indication. And for BD, we will leverage our robust IP portfolio and business develop to drive value and complement core gene editing technology capabilities.

Speaker 2

So how we executed against this strategy and these objectives in the Q1? Let us start with ReniCell. 1st, on enrollment. We've been very pleased with the growing patient and healthcare provider interest in ReniCell. Indeed, we are delighted to share that we have completed enrollment in the adult cohort of the RUBY clinical trial.

Speaker 2

Additionally, we have enrolled multiple patients and have more in screening in the adolescent cohort of our RWBY study, which was launched at the beginning of this year. And we continue to enroll beta thalassemia patients in our EDITAL study. Dosing continues in both the RUBI and EDITAL studies. 2nd, on clinical data, we remain on track to present a substantive clinical data set of at least 18 sickle cell patients with 2 to 21 months of clinical follow-up in the RUBY study in the middle of 2024 and we will share a further update by year end. We are also on track to present clinical data from the EDITHAL study of ReniCell in transfusion dependent beta thalassemia in the middle of 2024 and again by year end.

Speaker 2

Based on my will share more ReniCell data later on in this call. On the manufacturing front, I am pleased to share that we have promoted Greg Whitehead to the role of Chief Technology and Quality Officer, leading our technical development, technical operations and quality departments. Greg has more than 25 years of experience in the biotech industry and extensive cell and gene therapy clinical and commercial development expertise. Now, let's turn to in vivo and our pipeline development, where we continue to strengthen our in vivo discovery capabilities and continue lead discovery work on in vivo therapeutic targets in hematopoietic stem cells and other tissues. Importantly, we remain on track to establish in vivo preclinical proof of concept for an undisclosed indication by the end of the year.

Speaker 2

Our internal development efforts are differentiated by leveraging the indel CRISPR technology we already used to upregulate gamma globin expression through direct editing of the HBG-twelve promoter site in our ex vivo reticel program. Our in vivo approach is aimed at functional upregulation of gene expression in genetically defined diseases with a preliminary focus on rare and orphan patient populations. In the medium to long term, we intend to expand to more common genetically determined diseases. Linda Berkley, our CSO, will share more details on our in vivo strategy and progress towards building an in vivo pipeline later on in the call. Finally, what is happening in business development?

Speaker 2

In March, we signed a 2 year extension to the collaboration with Bristol Myers Squibb to research, develop and commercialize autologous and allogeneic alpha beta T cell medicines for the treatment of cancer and autoimmune diseases. We also have options to extend that collaboration for an additional 2 years. To date, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. 2 programs are currently in IND enabling studies and 4 programs are in late stage discovery. And the intellectual property, yesterday, oral arguments were held before the U.

Speaker 2

S. Court of Appeals for the Federal Circuit regarding an appeal of the Patent Trial and Appeal Board or PTAB's previous decision favoring Broad Institute in the U. S. Patent interference involving specific patents for CRISPRCas9 editing in human cells between the University of California, University of Vienna and Emmanuelle Charpentier or CDC and the Broad. We expect a decision on the case in the second half of twenty twenty four.

Speaker 2

Eric will share more BD and IP details later on in the call. We are energized by our progress and execution this quarter. With our sharpened strategic focus, our world class scientists and employees, our keen drive in execution and strong balance sheet, we continue to build momentum to progress our strategy to deliver differentiated editing medicines to patients with serious genetic diseases. Now, I will turn the call over to Beisong, our Chief Medical Officer.

Speaker 3

Thank you, Gilmore. Good morning, everyone. Let's talk about Rene Cel, which is on the clinical development for severe sickle cell disease and transfusion dependent beta thalassemia. As Gilmore shared, we are pleased that we have completed enrollment in the adult cohort of the Phase 1 to 3 RUBY trial and the dosing continues. In the adolescent cohort of the RUBI study, we have enrolled multiple patients and several more patients in screening.

Speaker 3

The interest and demand are high. I'm very pleased about how quickly we have moved in screening and enrollment of lead adolescent cohort. I would like to thank colleagues and editors and our clinical trial partners for the collaboration and hard work. And more importantly, I would like to thank patients, their families, investigators and the study side staff for their trust and support. In the EDIHAL trial for transfusion dependent beta thalassemia, we continue to move forward with enrollment and dosing.

Speaker 3

We look forward to sharing clinical data in the middle of this year and also at the year end. As I have shared, I visited and continue to visit our Rubi and Edidale clinical trial sites and speak with the investigators. I appreciate the enthusiasm and support from the investigators and study sites. I'm pleased with the momentum of renaCell in patient recruitment, Afrezza and dosing in both studies. I'm excited to hear from the investigators that patients dosed to the renaCell have already seen positive changes in their lives.

Speaker 3

As we shared in our February earnings call, we aligned with FDA that ruby clinical trial is now considered a Phase 1, 2, 3 trial for BLA filing. We also have alignment with the FDA on the study design, endpoints and sample size. We look forward to future discussions with FDA and continue the collaboration. Turning to clinical data, as Gilmore mentioned, we are on track to present a substantive clinical data set of sickle cell patients with considerable clinical follow-up in the RUBY study in the middle of 2024 and further update by year end 2024. What we will show, the RUBI data set were including clinical data from at least 18 sickle cell patients with a 2 to 21 month of follow-up And the EdiCell dataset will include clinical data from 7 patients with 4 to 12 months follow-up.

Speaker 3

We will present efficacy data including total hemoglobin, fetal hemoglobin and the vessel occlusive events or BOE for sickle cell patients in RWBY study and red blood cell transfusion or transfusion dependent beta thalassemia patient in Editale and safety data including neutrophil and plasma investment for both studies. As a reminder, in December 2023, we shared safety and efficacy data from 11 RUBI patients and 6 Adithale patients. Once again, the data confirmed the observation from our prior clinical readouts, including Ranasil drove early robust correction of anemia to a normal physiological range of total hemoglobin in sickle cell patients. Renal cell drove robust and sustained increase in fetal hemoglobin level in excess of 40%. All Rubi sickle cell patients remained free of vessel occlusive events following renal cell treatment.

Speaker 3

Rynocell treated sickle cell patients and transfusion dependent beta thalassemia patients have shown successful engraftment have stopped red blood cell transfusion. And the safety profile of Renesas observed today is consistent with biosolvent mybolytic conditioning and the autologous hemopoietic stem cell transplant. This data reinforce our belief that we have a competitive product and the product potentially differentiate from other treatments with a record correction of anemia. Thanks to the deliberate choice of our discovery we have made early in the program. The choice of CRISPR enzyme and the target to edit for increased fetal hemoglobin expression matters.

Speaker 3

Ranatel uses our proprietary ASK12A enzyme to up regulate HB-two twelve promoter. Based on the clinical data thus far, we believe that sustained normal levels of total hemoglobin could be a potential point of differentiation for RanaCell. Now, I'll turn the call over to Linda, our Chief Scientific Officer.

Speaker 4

Thanks, Baisong, and good morning, everyone. I'm happy to be talking to you this morning to share more details about our in vivo strategy and our progress towards building an in vivo pipeline. I would like to take a moment to remind you why we believe in vivo medicines will be a disruptive transformative development in medical history with the potential to address genetically determined diseases with durable and curative outcomes for patients. First, in vivo medicines may reduce the administration burden of delivering editing medicines to patients in need, which will provide for broader access to patients all around the world. 2nd, off the shelf administration may allow for scalable manufacturing and lower cost to produce.

Speaker 4

Based on these two principles, we believe that in vivo gene editing will provide accessible cures for genetic diseases and therefore maybe the most disruptive development in medical history. So how will Editas position itself? There are many monogenic diseases that can potentially be cured with a gene editing approach. We have said that we will at first target the development of treatments that are clearly differentiated from current standard of care and that will leverage the aspects of CRISPR editing that give it a unique advantage over other therapeutic modalities. Our internal development efforts are differentiated by leveraging the indel CRISPR technology we use to up regulate gamma globin expression through direct editing of the HBG-one-two promoter site in our ex vivo RENACEL program.

Speaker 4

Our in vivo approach is aimed at functional upregulation of gene expression in genetic diseases in rare and orphan patient populations from which we intend to expand to more common diseases. I'm also pleased to share several progress updates as we advance our in vivo capabilities towards our long term vision of being a leader in in vivo programmable gene editing. 1st and most importantly, as Gilmore mentioned, we remain on track to establish in vivo preclinical proof of concept for an undisclosed indication by the end of the year. Editas is well positioned with established capabilities in the 4 main components of in vivo gene editing medicine: 1, guide RNA 2, editing enzyme 3, messenger RNA and 4, delivery technology. And we are currently evaluating lipid nanoparticles for delivery of gene editing cargo into multiple tissue types with multiple companies.

Speaker 4

Additionally, we are evaluating next generation delivery technology. 2nd, our in vivo capabilities with the potential to be used in developing transformative in vivo gene editing medicines are demonstrated by the preclinical data we are presenting at the American Society of Gene and Cell Therapy or ASGCT Annual Meeting and 3 presentations taking place on Thursday Friday of this week. On Friday, in an oral presentation, we will share in vivo preclinical data from mouse studies using lipid nanoparticle mediated delivery of an optimized guide RNA and engineered AS cast 12A messenger RNA. In poster presentations on Thursday Friday, we will share preclinical data demonstrating ASKaptLA guide RNA modifications that enable high potency gene editing in multiple cell types, including in the liver and improved gene editing outcomes in vivo, enabling the development of in vivo gene editing medicines and research on identifying potent large serum recombinases, LSRs, as a foundation to develop novel in vivo gene editing technologies for whole gene knock in, expanding potential in vivo gene editing targets for developing medicines. 3rd, Editas CRISPR based in vivo gene editing capability has been clinically validated.

Speaker 4

Notably in 2020, Editas is the 1st company ever to treat a human with an in vivo delivered CRISPR based gene editing medicine EDIT-one hundred and one. In fact, earlier this week, the New England Journal of Medicine published a manuscript entitled Gene Editing for CEP290 Associated Retinal Degeneration detailing our formal lead development candidate EDIT-one hundred and one for the treatment of leburs congenital amaurosis type 10 or LCA10. Edith has established clear in vivo human proof of concept in 2022 and we are pleased that the results from this groundbreaking clinical trial were published by the New England Journal of Medicine. These progress updates demonstrate Editas' execution on our in vivo strategy and our proven in vivo gene editing capabilities. And I look forward to sharing more details about our in vivo development strategy and our progress towards building an in vivo pipeline later this year.

Speaker 4

Now, I will turn the call over to Eric, our Chief Financial Officer.

Speaker 5

Thank you, Linda, and good morning, everyone. I'm happy to be speaking to you and I'm excited to provide updates on our business development achievements, intellectual property and financial results for the Q1 of 2024. First, in regard to business development, as Gilmore mentioned, in March we announced a 2 year extension to the collaboration with Bristol Myers Squibb to research, develop and commercialize autologous and allogeneic alpha beta T cell medicines for the treatment of cancer and autoimmune diseases. We also have options to extend the collaboration for an additional 2 years. To date, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date.

Speaker 5

2 programs are currently in IND enabling studies and 4 programs are in late stage discovery. As a reminder, for each new experimental medicine that Bristol Myers Squibb develops and commercializes using opted into genome editing tools, Bristol Myers Squibb will pay Editas Medicine potential future milestone payments. Following the approval of any products resulting from the collaboration, Editas Medicine is also eligible to receive tiered royalties on net sales. We are pleased that our Bristol Myers collaboration has proved to be a productive partnership and we are committed to future collaborations and partnerships that will allow for the continued access and advancement of gene editing. And in IP, as Gilmore mentioned, yesterday the oral arguments were held before the U.

Speaker 5

S. Court of Appeals for the Federal Circuit regarding the CVC's appeal of the PTAB's decision involving patents for CRISPRCas9 editing in human cells. As you know, the Broad Institute has previously prevailed 3 times against the CBC, twice with the PTAB and once at the Federal Circuit. The Federal Circuit's review will determine whether the PTAB correctly applied the law. It is important to remember the court will not hear new evidence.

Speaker 5

An appellate court decision in the Broad's favor would reaffirm Editas' position as the exclusive licensor of the patents covering Cas9 used in human medicines in the U. S. It's also important to remember that only a small fraction of the IP we licensed from the Broad are involved in the ongoing USPTO interference proceedings. We expect a decision on the case in the second half of twenty twenty four. We remain confident that the Broad will once again prevail.

Speaker 5

Our IP portfolio of foundational U. S. And international patents covering Cas9 and Cas12 used in human medicines are a source of meaningful value as we believe that globally there are more than 100 Cas9 Cas12a programs in development worldwide with the majority of the programs being developed by 10 companies. We believe these potential deals represent a potential material source of non dilutive capital as evidenced by our deal in the Q4 of 2023 that extended our cash runway by 2 quarters. We look forward to future discussions.

Speaker 5

And now I'd like to refer you to our press release issued earlier today for a summary of our financial results for the Q1 of 2024. I'll take this opportunity to briefly review a few items for the quarter. Our cash, cash equivalents and marketable securities as of March 31, $377,000,000 compared to $427,000,000 as of December 31, 2023. We expect our existing cash, cash equivalents and marketable securities together with the near term annual license fees and contingent upfront payment payable under our license agreement with Vertex to fund our operating expenses and capital expenditures into 2026. Revenue for the Q1 of 2024 was $1,100,000 compared to $9,900,000 for the same period in 2023.

Speaker 5

The decrease relates to the January 2023 one time sale of the company's wholly owned oncology assets and related licenses. R and D expenses this quarter increased by $11,000,000 to $49,000,000 in the Q1 of 2023. This increase relates to additional clinical and manufacturing costs that support the continued progression of the company's rent a cell program. The increase is also attributable to one time payments related to sub license and license obligations. Editas will continue to incur these types of payments as we and our collaboration partners advance certain license programs in the gene editing space.

Speaker 5

G and A expenses for the Q1 of 2024 were $19,000,000 which decreased from $23,000,000 in the Q1 of 2023. The decrease in expense is primarily attributable to one time professional service expenses related to the 2023 strategic initiatives and business development activities as well as reduced legal and patent costs. With our BD and IT activity and a cash runway into 2026, Editas remains in a strong financial position. We have ample resources to continue the advancement of our RENASEL program, support the progression of our in vivo capabilities to develop our pipeline and leverage our strong IP position position for additional business development and licensing opportunities. With that, I will hand the call back to Gilmore.

Speaker 2

Thank you, Eric. We are proud of our progress in the Q1 of 2024 and we look forward to continue to accelerate the momentum in 2024. As we continue to evolve from a development stage technology platform company into a commercial stage gene editing company, We look forward to continuing our transformation and sharing our progress with you. As a reminder of our 2024 strategic objectives, for ReniCell, we will provide a clinical update from the ReniCell RWBY trial for severe sickle cell disease and the Edit Cell trial for transfusion dependent beta thalassemia in mid-twenty 24 year end 2024. We have now completed the adult cohort enrollment and have started enrolling patients in the adolescent cohort in RWBY.

Speaker 2

We will also continue enrollment in edithal and dosing in both trials. For our in vivo pipeline, we will establish in vivo preclinical proof of concept for an undisclosed indication. And for BD, we will leverage our robust IP portfolio and business development capabilities to drive value and complement core gene editing technology capabilities. As we shared today, we are making significant progress in all three pillars of our strategy this quarter, including ReniCell, in vivo and business development, including intellectual property. We entered 2024 with great momentum and I am proud of the Editas team's significant progress towards becoming commercial stage company and on developing clinically differentiated transformational medicines for people living with serious previously untreatable diseases.

Speaker 2

As always, we could not achieve our objectives without the support of our patients, caregivers, investigators, employees, corporate partners and you. Thanks very much for your interest in Editas and we're happy to answer questions. Thank you.

Operator

Thank you. We will now be conducting a question and answer session. Our first question comes from Samantha Simino from Citi. Please proceed.

Speaker 6

Hi, good morning and thanks very much for taking my questions. I'm wondering about your in vivo pipeline and the proof of concept that you're expecting by the end of this year. What would be the bar for success that you're looking for in this program? Thank you.

Speaker 2

Thanks very much, Samantha. I'm going to ask Linda to address that.

Speaker 4

Thank you, Sam. Thank you for the question. Proof of concept for high efficiency delivery and editing for our target of interest in vivo in this preclinical POC that will give us confidence in our ability to target the target of interest. We are going to be sharing more information on this at a future date. Thank you for the question.

Operator

Our next question comes from Joon Lee from Truist Securities. Please proceed.

Speaker 7

Hey, congrats on the progress and thanks for taking our question. An interesting update on your disclosure is the plan to identify large serum recombinations, which implies sort of a newer approach to many of your that many of your peers are also developing some call it gene writing, some call it pasting. Does the size of the recombinase mediated insertion allow for inserting a coding sequence for dystrophin, for example? And are you able to comment on whether DMD is out of the question regarding your in vivo aspirations?

Speaker 2

Thank you. Thanks very much, June. I'm going to have Linda take that.

Speaker 4

Yes. Thank you for commenting. We're excited about the LSR technology that we're disclosing here. We are identifying many different novel LSRs. We're not disclosing at the moment the size of the integrations that can be accommodated by these large serum recombinations, but we have quite a few novel LSRs that we've identified and we're further characterizing them.

Speaker 4

Thank you for the question.

Operator

Our next question comes from Mary Kate Davis from Bank of America. Please proceed.

Speaker 8

Good morning. Thanks for taking my question. Looking at the ReniCell program here, how are you guys looking at the mid year ReniCell update compared to the year end update here? As follow-up time progresses, what should we look for from treated patients in terms of safety and efficacy moving forward? Thank you.

Speaker 2

Thanks, Mary Kate. Baisong is going to take that one.

Speaker 3

Yes. Thanks, Mary. So in this middle year release, we expect to have at least 18 patient data for RUBY study. And within the 18 patients and 4 of them will have 12 or longer, 12 to 21 months of exposure and the 7 will have 5 months to 12 months exposure and another 7 with 2 to 5 months exposure. With that, we feel this data is very meaningful to see the direction, not only the increase of total hemoglobin normalization of our total hemoglobin and increase of fetal hemoglobin, but also the durability of the study and the impact from efficacy perspective, for example, the free of vessel occlusive events.

Speaker 3

For the EDI sales study, we will have patients from at least the 7 dose patient with 4 to 12 months of exposure, which also will be very meaningful that is compared to the December release, we have 11 Rubi patients and 6 Adafale patients. So that substantial more data will help us to understand group much better. Thank you.

Operator

Our next question comes from Jack Allen from Baird. Please proceed.

Speaker 9

Congratulations to the team on the progress and thanks for taking the question.

Speaker 3

I'm going to stick with

Speaker 9

the ReniCell program. I was hoping you could provide some color on dosing of the pivotal cohort. I know you've commented on the adult cohort being fully enrolled, but have all those patients received therapy? Any other comments you can provide as it relates to the size of the cohort that you've agreed to with regulators would be very helpful? Thanks so much.

Speaker 2

Thanks very much, Jack. I'll answer the first part and then pass it to Basant. Tobeyak, maybe give a little more color to regulatory interactions. We have obviously completed the adult enrollment, which we're actually very excited about, not least because that is in the context of 2 approved therapies. So it really is a very concrete reflection of the enthusiasm that Baisong has found and described, indeed increasing enthusiasm about our program with his visits to sites and conversations with investigators, health care providers and indeed with patient advocacy groups.

Speaker 2

We have scheduled many of those patients already for dosing and we'll give you further updates on the progress of dosing at a later date. And with regard to the regulatory color, I think, Baisong, you might want to

Speaker 10

maybe just share a little more.

Speaker 3

Yes. For regulatory, as we shared that we have alignment with FDA that the RUBY study is a Phase 1, 2, 3 study for EOF filing. And we also have alignment on the sample size, duration and study design of that. So we continue to have a collaboration with FDA on the further discussion about this program.

Speaker 2

Great. Thank you.

Operator

Our next question comes from Gena Wang from Barclays. Please proceed.

Speaker 11

Thank you. If I may, very quick two questions. First, should we read into your AS GCT presentation for in vivo indication such as glaucoma? And second, I know you mentioned also a little bit, but when we look at the current approved genomic therapy for sickle cell, we still have a 10% patient relapse with VOV events. What do you think is the key factors that we should look into for the potential differentiate durability with hopefully 100% control rate?

Speaker 2

Thanks very much, Gina. I'm going to ask Linda to handle the first part of your question around the ASGCT and then Baisong can talk about durability, what we're seeing today.

Speaker 4

Yes. Thank you very much, Dina. Primary open angle glaucoma is obviously an area of very high unmet need. And while we conducted those studies because of that, we are not currently pursuing that indication, but we were able through those studies to really demonstrate impressive preclinical POC and showcase our in vivo capabilities with respect to 3 components: our ability to deliver lipid nanoparticles in vivo with our gene editing cargo our proven capability of our proprietary enzyme, ASCAS12A, to edit in vivo and our guide modifications to enhance a gene editing potency. So these capabilities really position us well for delivering in vivo gene editing medicines, and we're really pleased with the ASGCT disclosures.

Speaker 4

Thank you.

Speaker 3

Yes. I can now take up on the question about the BOE relapse for sickle cell patients. First, I would like to say, I want to congratulate the entire field for the effort in treating sickle cell disease, including the recent approval of the 2 molecule. And so I think what we see is that with the continued effort of all of us, we will continue to improve and transform the treatment for sickle cell disease patients. With the renal cell and we are still continue to collect the clinical data.

Speaker 3

As I mentioned, we expect that this is a different not only competitive but differentiated molecule and with the normalization of the total hemoglobin correction of anemia. We're looking forward to see our own data on the BOE. As we reported so far, we have seen all those patients dosed with renal cell is free of the BOE

Operator

event. Thank you. Our next question comes from Manny Foroohar from Leerink Partners. Please proceed.

Speaker 12

Hi, good morning. This is CJ on for Mani. Thanks for taking our question. Ours is following the agreement with Vertex last year, just how are you thinking about future IP monetization opportunities?

Speaker 2

Thanks very much. I'm going to ask Eric to address that question.

Speaker 5

Yes. Thanks for the question. Obviously, as we said in the transcript, we view the future potential royalty monetization and licensing activities as an integral and very important source of non dilutive capital. As you know, these are foundational IP patents which are applied to just about everybody's projects in Cas9, Cas12. And we expect to have conversations with those folks as soon as we

Speaker 13

can. Thank you.

Operator

Our next question comes from Brian Chang from JPMorgan. Please proceed.

Speaker 7

Hey guys, thanks for taking our question this morning. Can you just remind us what's your latest thinking around the timing of holding discussion with regulators on sickle cell? And just given the data that you are going to present mid year, any updates and color on the timing of holding a productive conversation with regulators will be appreciated. Thank you.

Speaker 2

Thanks very much, Brian. I'm going to ask Baisong to talk about that sort of I think your two questions really, which is about what the data are in the middle of the year and how they integrate with our discussions with regulators.

Speaker 3

Yes. So Brian, we as I mentioned, we are very pleased with the data we're going to release in the middle of the year and which is substantive and also give us good direction how much we will get and to have, for example, a dataset to have equivalent to the cash GV BLA filing, for example, right. So that's kind of one part of that. We're very happy to see the amount of data and the patient outcome upon the data. And then the other thing is about the regulatory engagement.

Speaker 3

As I mentioned, we already have aligned this Phase 3 study to support the BLA and we have continued engagement with FDA. We have not disclosed all those details of the interaction yet. But as a reminder, we have RMED designation and which allow us to have frequent interaction with agency, but also with a high level interaction with agency. And this of course help give us opportunity for potential priority review and rolling submission. So we're very excited to the direction.

Speaker 3

We continue to have engagement and collaboration with FDA.

Speaker 7

Thank you, Beifeng.

Operator

Our next Our next question comes from Eric Schmidt from Cantor Fitzgerald. Please proceed.

Speaker 10

Thanks for the question and congrats on the progress. Are you able to give the approximate number of patients who are enrolled in the RUBY trial with sickle cell disease? And then, it sounds like you've been able to make pretty good progress in enrollment in that study despite the availability of commercial cell therapies. I was just wondering at centers that have both experimental and commercial cell therapy available, maybe Baesung could talk a little bit about what's driving the decision to use the Editas product over others? Thanks.

Speaker 2

Thanks very much, Eric. Based on we can update you on where our clinicaltrials.gov sets as a target for the cohort in our trial. And then, obviously build on his perceptions of why we're doing so well with enrollment, even in the context of commercial therapies being available.

Speaker 3

Yes. Thanks, Eric. We are very pleased with the momentum by the enrollment in both the adult cohort and the adolescent cohort. And for the adult cohort, we shared that in February those we enrolled 40 patients. Now we know slightly more than 40 patients and therefore we closed the adult cohort enrollment.

Speaker 3

And for adolescent cohort, we started like beginning of this year, we already enrolled multiple patients and have multiple patients screenings. We're very pleased with that. Then as I mentioned, I'm on the road all the time to visit our investigators and the study sites. And then they really feel that when is actually there believe the Ranacell based on the MOA, based on the data we have continued to sharing on that. I also give credit the entire field been working on that with the 2 gene therapy approved for sickle cell is also the increased interest in the direction of the gene therapy for sickle cell disease.

Speaker 3

So that's how we see over the last year or so we see really great momentum that for renal cell enrollment, especially after we release our data.

Operator

Our next question comes from Jay Olson from Oppenheimer and Company. Please proceed.

Speaker 14

Hey, congrats on all the progress and thank you for taking the question. Can you talk about the timing of the collaboration extension with Cristal? Was there some new data that triggered the new collaboration? And is there any color on what new data Bristol may have seen? And then separately, can you talk about any work that you've done on developing a milder conditioning agent?

Speaker 14

Thank you.

Speaker 2

Well, what I want to do is ask Eric to address the question about the BMS. What I do want to say, I can address the conditioning, which is that just at our last earnings, we talked that we are going to continue monitoring the space. We have significant context in the academic and non academic worlds around the field. But we have actually really deployed our efforts and our resources internally to focusing on our in vivo pipeline, including developing hematopoietic stem cells. The rationale for that being that we see that where a milder conditioning therapy is actually approved, it would be used universally and adopted universally in transplant centers across multiple indications, including

Speaker 7

stem cell transplantation

Speaker 2

for hemoglobinopathies. And with that, I'm just going to pass to Eric just to talk about the BMS deal.

Speaker 5

Yes, thanks for the question. With respect to the timing of the renegotiation or the extension, obviously we put out a press release in the very recent past week or 2 ago, something like that. And that would give you an update on the timing. I'd say with respect to the data, Bristol Myers, as you know, recently completed a portfolio review and we are pleased to see that all of the projects that we're working on them are continuing to move forward. Think if we would leave discussion of specific programs to them to talk about anything that they're seeing in those programs.

Speaker 5

I would highlight the fact that at their most recent R and D Day, last September, which I think was the first one they've done in several years, they did mention 6 products, on their pipeline chart, which were using our technology. So I would refer you to their R and D disclosures from that meeting to get an update on the work that they're doing with us. But we are very excited about working with them. This has been a partnership that has survived several mergers and several portfolio reviews. So we're very excited about what we're seeing.

Speaker 5

Thank you.

Operator

Our next question comes from Phil Nadeau from TD Cowen. Please proceed.

Speaker 10

Hi, this is Alex on for Phil. Thanks for taking my question. So given the association between total hemoglobin levels and organ function, Do you plan to utilize any quantitative endpoints, basically assessing end organ function in the RUBI trial? And if so, what might those look like and when can we maybe expect initial data? Thanks.

Speaker 2

Thanks very much, Alex. I'm going to ask Bison to address that question.

Speaker 3

Yes. Thanks, Alex. We certainly have measurements for the end organ function. We look into that several major organ system to monitor the function improvement. For example, we monitor the liver function not only with these different lab values, we're looking to pulmonary function to check the respiratory system and we also have cardio echo and other measures talking to measure the cardiovascular system in that too.

Speaker 3

So we are looking forward to see more data on that and give us more understanding of how the end organ function may behave after the treatment. Just a reminder that we also of course look into the not only sickle cell but also other area in terms of the anemia, how that impact function and how that correction of anemia may be able to improve that function after the treatment. And in sickle cell specifically over the last couple of years you already see more publications about end organ function given after the allogeneic transplant to treating sickle cell patients. We are very excited on that. But just to be very honest to ourselves, right, this field is still fairly new and we see some really good publication and direction in this and we're looking forward to our own study as well as the literature on this field.

Speaker 10

Great. Thank you.

Operator

Our next question comes from Yanan Xu from Wells Please proceed.

Speaker 7

Thanks for taking our questions. So first on the differentiation of total hemoglobin normalization. I was wondering, have you had feedback from sickle cell treaters on that differentiation and whether there's any hesitancy or pushback that perhaps the current level of hemoglobin achieved by the marketed product is sufficient? How much of that kind of thinking is out there? And on the in vivo side, I was wondering, are you focused on 1st in class targets or perhaps not 1st in class targets, but hoping to have a differentiation on specificity and transduction efficiency, etcetera?

Speaker 7

Thanks.

Speaker 2

Thanks very much, Yanan. So I'm going to ask Baisong to talk about the differentiation of total hemoglobin and then I'll ask Linda just to talk about our approach to 1st in class or clear differentiation and where we would see that with our approach to function of regulation.

Speaker 3

Thanks, Allen. I mean certainly we talk about the investigators as well as the KOLs and sickle cell treaters for our differentiation and how we may be able to see and what is the position of this molecule. And when we're talking to those hematologists and sickle cell treaters that see our data And when the hematologist mentioned that it is no brainer, it is better if you have a 16 gram per deciliter versus 10 gram per deciliter of total hemoglobin. And then they also I mentioned that the enthusiasm of our study and there are quite a few knowledgeable hematologists. They see the difference among several molecules And when investigator said that he was waiting for our trial and did not participate in other.

Speaker 3

So those are the anecdotal examples on that. As I mentioned earlier, we certainly want to look forward to see the clinical data.

Speaker 2

It's also worth highlighting of course that the FDA has recognized that 1 gram per deciliter difference is meaningful or certainly likely to predict a clinically meaningful benefit and that they use that threshold to give an accelerator approval to Otrarieta in the past.

Speaker 3

Yes. Talking about that, this is also when we communicate with FDA, this is also a point we have been in discussion with FDA too.

Speaker 2

So thanks very much, Peisong. Linda, just regarding in vivo and where our focus is.

Speaker 4

Yes. In vivo, our in vivo approach is aimed at functional upregulation of gene expression, genetically determined diseases. And this strategy positions us very well to be differentiated from others in terms of our targets and our target editing strategies. And what this means is that we can go after targets that others can't go after. And so from an indications perspective, we can go after indications that perhaps others can't go after and so we could have a first in class strategy.

Speaker 4

Also within a given indication, we could devise a targeting strategy that would be best in class, if you will. So we can have 1st in class strategies as well as best in class opportunities. I hope that answers your question.

Speaker 7

Yes. Thank you. Very helpful. Thanks for all the answers.

Operator

Our next question comes from Luca Eze from RBC Capital. Please proceed.

Speaker 15

Great. Thanks so much for taking my questions and congrats on all the progress. Maybe just a quick one on ReniCell and the filing strategy. What's the vision here for the BLA? Are you planning to file adults and adolescents concurrently or sequentially?

Speaker 15

Color there much appreciated. And then maybe quickly on the Middle East, can you just talk about the opportunity for sickle cell disease in the Middle East? Vertex seems really, really excited about that market. So wondering what's your strategy there to potentially tap that market? Are you still focused on the partnership?

Speaker 15

Can you potentially access that via distributor? Again, any thoughts there are much appreciated. Thanks so much.

Speaker 2

Happy to do thanks very much, Lucas. So I'll ask Baison just to talk about our regulatory strategy as far as we have shared it. And then Karen can talk about just how we're looking at and thinking about the Middle East and frankly in the context of the rest of world.

Speaker 3

Yes. Thanks, Luca. We are very pleased with the interaction with agency and continued interaction with agency about the renal cell for the RWBY study as a Phase 3 study to support the BLA and all the front of the Phase 3 study we have alignment on that and we have continued conversation with FDA on this route. We have not shared the specifics about the date of the BLA or the indication of adult alone or adolescent. But as we shared, we are very pleased with the enrollment for both adult cohort as well as adolescent cohort.

Speaker 3

So that give us great position for this molecule. Thank you.

Speaker 16

Great. Luca, thanks for the question about Middle East and certainly just the populations outside the United States. And there's absolutely a number of geographies where there is a significant population of sickle cell patients and really high unmet need beta thalassemia as well. What I'd say is our continued drive to execute in the U. S.

Speaker 16

And to move RENACEL forward with differentiation just continues to support the opportunity for us to partner at the appropriate time. And that's certainly something that we've said we are open to and we'll certainly provide more color in the future as Steve

Speaker 15

Seedhouse from Raymond James.

Speaker 13

Please proceed. Hi, Steve. Hi, Steve. Good morning, Steve. Good morning, Steve.

Speaker 13

Good morning, Steve. Good morning, Steve. Good morning, Steve. Good morning, Steve. Good morning, Steve.

Speaker 13

Good morning, Steve. Good morning, Steve. Good morning, Steve. Good morning, Steve. Good morning, Steve.

Speaker 13

Good morning, Steve. Good morning. Good morning, Steve. Good morning, Steve

Operator

Steve Seedhouse from Raymond James. Please proceed.

Speaker 17

Hi, thank you. This is Nick on for Steve. We actually had a longer term question. To what extent can you leverage the infrastructure that Vertex is already building out for Cazgibbean? And will EDIT-three zero one be able to plug into the existing authorized treatment centers once launched?

Speaker 17

Thank you.

Speaker 2

Thanks very much. Thanks very much, Nick. I'm going to ask Karen to address that.

Speaker 16

Yes. Thank you, Nick, for the question. First, we'd say I'd say that I'm really pleased to see some of the initial progress for the other therapies being able to get patients started. We always anticipated that it would be a dipping many centers starting to dip their toe as they build the infrastructure and they gain the confidence. So to answer your question, absolutely.

Speaker 16

We've always said that in this kind of market of the complexity of the ex vivo, being a SaaS follower is absolutely an advantage. We also, on our own, have a really strong base of over 20 clinical sites in the U. S. With very strong enrollment and relationships that we're leveraging and those relationships and the guidance they're giving us will be really pivotal for us as well. But this is a field that will benefit from the increase in education with patients, which Baisong mentioned also helps with our enrollment and just building the infrastructure.

Speaker 16

But we are engaged on the KOL, the patient advocacy as well as on the payer front to ensure that we're prepared. So thanks for the question.

Speaker 3

Thank you.

Operator

Our next question comes from Jack Allen from Baird. Please proceed.

Speaker 9

Great. Thanks so much for taking the quick follow-up here. I just wanted to touch on Renesal one more time and ask when we might hear a little bit more about the differentiation as it relates to the treatment process. Have you provided any color on the number of apheresis cycles and how editing efficiency of the Cas12a enzyme may allow you to be more efficient in manufacturing the process?

Speaker 2

Thanks very much, Jack. So I'm going to ask Baisong to talk about that.

Speaker 3

Yes. Thank you. We are we have not shared specifics about the number of cycle on the free sales. What I mentioned before was, since I joined, we actually worked together with our internal as well as a free speech external free speech expert. We actually have protocol management to improve the apreasys cycle and also provide assistance to the study side to for the apheresis cycle, which is significant because it's reduced patient burden, it's a smooth manufacturing process.

Speaker 3

We are very pleased to see the progress in that front. And just to add on that, we are hoping this clinical experience will be very much helpful for our commercial Enduva.

Operator

Our next question comes from Manny Foroohar from Leerink Partners. Please proceed.

Speaker 12

Hi. Thank you for taking our follow-up question. Kind of similar to the last question, you previously talked about optimizing the vein to vein process. Would you be able to walk us through how RenTel could provide advantages from either both operational or logistics perspective? Thank you.

Speaker 2

So, Baisong, I'm going to ask I'll ask Baisong to address that.

Speaker 3

Yes, yes. Happy to. We are over this process really working together that with the study sites to optimize these process and that's coming from multiple factors. One of the factors just mentioned is biophoresis. The other factor is the logistics and we provide support on that.

Speaker 3

The third factor is actually patient condition as we know that we are treating the severe sickle cell disease and before the renal cell treatment that can have multiple BOE per year and that also can impact the ventilator time.

Speaker 16

Manny, this is Karen. I would just add that again in the fast follower position, one of the things

Speaker 13

that it gives us the opportunity to do

Speaker 16

is to really understand as the the what's not working, what they need to see differently and really making sure that Editas sets ourselves up as the partner of choice. And so we're working very hard on that and we'll certainly talk about that at a later time.

Speaker 12

Great. Thanks so much for taking your question.

Operator

Ladies and gentlemen, this concludes today's call. Thank you once again for your participation. You may now disconnect.

Powered by Quartr

Key Takeaways

  • Editas has completed adult cohort enrollment in the RUBY trial and begun adolescent dosing, with mid-2024 and year-end updates planned—early data show normalization of total hemoglobin, sustained fetal hemoglobin >40%, absence of vaso-occlusive events and transfusion independence in beta thalassemia.
  • Editas’ in vivo pipeline remains on track to achieve preclinical proof of concept for an undisclosed indication by year-end 2024, leveraging proprietary AsCas12a enzyme, optimized guide RNAs and lipid nanoparticle delivery with encouraging data presented at ASGCT.
  • The collaboration with Bristol Myers Squibb was extended two years (with options for two more), covering 13 opted-in programs across 11 gene targets, including two in IND-enabling studies and four in late-stage discovery.
  • Key IP developments include oral arguments at the Federal Circuit in the CRISPR-Cas9 patent appeal, with a decision expected in H2 2024—an outcome that would reaffirm Editas’ exclusive U.S. license to Cas9/Cas12a and unlock non-dilutive funding opportunities.
  • As of March 31, Editas held $377 million in cash, equivalents and securities—providing a runway into 2026—while Q1 revenue reflected the prior year’s one-time oncology asset sale and higher R&D investment to advance ReniCell.
AI Generated. May Contain Errors.
Earnings Conference Call
Editas Medicine Q1 2024
00:00 / 00:00